Levetiracetam Actavis Group 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0029 
C.I.2.a - Change in the SPC, Labelling or PL of a 
21/06/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IG/1612 
A.1 - Administrative change - Change in the name 
31/05/2023 
and/or address of the MAH 
SmPC, 
Labelling and 
PL 
IA/0027 
B.III.1.a.2 - Submission of a new/updated or 
22/03/2023 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0026 
C.I.2.a - Change in the SPC, Labelling or PL of a 
29/06/2022 
23/05/2023 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IB/0025 
C.I.2.a - Change in the SPC, Labelling or PL of a 
25/05/2021 
21/06/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0024/G 
This was an application for a group of variations. 
16/04/2021 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
Page 2/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
IB/0023/G 
This was an application for a group of variations. 
22/12/2020 
21/06/2021 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0022 
B.IV.1.a.1 - Change of a measuring or administration 
09/04/2020 
n/a 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
IB/0021 
C.I.2.a - Change in the SPC, Labelling or PL of a 
22/01/2020 
24/09/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 3/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0020 
C.I.2.a - Change in the SPC, Labelling or PL of a 
11/09/2019 
24/09/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0019/G 
This was an application for a group of variations. 
31/05/2019 
n/a 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0018 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/10/2018 
13/09/2019 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
N/0017 
Minor change in labelling or package leaflet not 
20/03/2018 
13/09/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0016 
B.III.1.a.2 - Submission of a new/updated or 
19/01/2018 
n/a 
Page 4/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0015 
C.I.2.a - Change in the SPC, Labelling or PL of a 
20/01/2017 
23/10/2017 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0014 
C.I.z - Changes (Safety/Efficacy) of Human and 
28/11/2016 
23/10/2017 
PL 
Veterinary Medicinal Products - Other variation 
R/0012 
Renewal of the marketing authorisation. 
23/06/2016 
08/08/2016 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
the CHMP considered that the benefit-risk balance of 
PL 
Levetiracetam Actavis Group in the approved indication 
remains favourable and therefore recommended the 
renewal of the marketing authorisation with unlimited 
validity. 
IAIN/0013 
B.III.1.a.3 - Submission of a new/updated or 
24/06/2016 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IB/0011 
C.I.2.a - Change in the SPC, Labelling or PL of a 
08/03/2016 
08/08/2016 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
Page 5/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0009/G 
This was an application for a group of variations. 
16/12/2015 
08/08/2016 
SmPC, 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.f.1.b.2 - Stability of FP - Extension of the shelf 
life of the finished product - After first opening 
(supported by real time data) 
Labelling and 
PL 
IAIN/0010 
B.III.1.a.1 - Submission of a new/updated or 
17/11/2015 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
N/0008 
Minor change in labelling or package leaflet not 
07/09/2015 
08/08/2016 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0007 
C.I.8.a - Introduction of or changes to a summary of 
20/05/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
N/0006 
Minor change in labelling or package leaflet not 
06/02/2015 
08/08/2016 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0005/G 
This was an application for a group of variations. 
21/05/2014 
n/a 
B.II.e.4.a - Change in shape or dimensions of the 
container or closure (immediate packaging) - Non-
sterile medicinal products 
Page 6/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IB/0004/G 
This was an application for a group of variations. 
16/04/2014 
15/12/2014 
SmPC and PL 
To update the SmPC and package leaflet with the 
tabulated list of adverse reactions in section 4.8 with 
“hyponatraemia” and in section 4 of the PIL including 
“decreased blood sodium concentration”. 
To update 4.8 of the SmPC to include ‘drug reaction 
with eosinophilia and systematic symptoms (DRESS)’ 
as a rare adverse drug reaction. The package leaflet 
was updated accordingly. 
All changes have been made in line with the 
originator product. In addition the contact details of 
the local representatives in BE, CZ, CY, LU and EL 
were updated in the package leaflet. Furthermore 
minor changes in the DK, EL, FI, HR, HU, IT, LV, PL 
and RO Product Informations (PI) have been 
performed to keep the PI in line with the originator 
product. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 7/9 
 
 
 
 
 
 
 
 
 
 
 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0003 
C.I.2.a - Change in the SPC, Labelling or PL of a 
19/12/2013 
15/12/2014 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
N/0002 
Minor change in labelling or package leaflet not 
25/09/2013 
15/12/2014 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0001 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/09/2012 
29/10/2012 
SmPC, 
Following CHMP adoption of safety variations to the 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
Labelling and 
Marketing Authorisations for Keppra, dated 19 April 2012 
PL 
section 4.8 of the SmPC for Levetiracetam Actavis Group 
was updated in order to add 'panic attack' as an 
undesirable effect. The Package Leaflet was updated in 
accordance. 
Moreover, the description of pancytopenia, erythema 
multiforme, Stevens-Johnsons syndrome and toxic 
epidermal necrolysis in section 4 of the Package Leaflet was 
also updated. 
The PI was brought in line with the latest QRD template, 
version 8. 
Additionally, local contact details for Netherlands, Greece, 
Poland and Slovenia have been updated. 
Page 8/9 
 
 
 
 
 
 
 
 
 
 
 
Page 9/9 
 
 
 
 
 
 
